Santanu has more than 20 years of experience managing and supporting strategic marketing and commercial decisions across the product lifecycle for life sciences organizations in both agency and industry fields around the world. His consulting experience spans pharmaceutical and biotechnology companies across all major therapeutic areas, including rare diseases and cell & gene therapies covering both oncology & non-oncology diseases.
Santanu has more than two decades of experience advising pharmaceutical and biotechnology organizations on pricing and access strategy decisions across the product lifecycle, including asset evaluation, pre-launch planning, clinical decision support, launch planning and post-launch loss of exclusivity. He has worked with organizations across the U.K. and Europe representing all major therapeutic areas including cardiovascular, diabetes, urology, gastroenterology, oncology and medical device and medical equipment.
Throughout his career, Santanu has developed account, payor landscape and pricing strategies for a variety of novel products. He has led commercial strategy assessments to support startup biotechnology companies, and managed clinical risk assessments to align clinical, regulatory and medical teams.
Prior to joining Huron, Santanu served as a vice president for the market research firm GfK. He ran his own healthcare consulting company for more than 10 years, advising global clients on due diligence and product commercialization strategy. He has also worked in sales and marketing at Wyeth Labs, SmithKline Beecham (now GlaxoSmithKline) and IMS Global Services.
Santanu holds an MBA in strategic marketing from Imperial College, London, and a Bachelor of Science with honors in biochemistry from the University of London.
Santanu is a member of several industry and professional organizations, including ISPOR, the Association of the British Pharmaceutical Industry (ABPI), Market Research Professionals and the Life Sciences Reimbursement Group.